Non-small Cell Lung Cancer
Conditions
Keywords
Preoperative chemoradiotherapy, stage IIIA, N2
Brief summary
The main objective of this trial is to compare feasibility and efficacy of sequential neoadjuvant chemoradiotherapy with 44Gy concomitant boost to neoadjuvant chemotherapy alone. Secondary objectives are to assess the value of position emission tomography (PET）in predicting pathological response and event-free survival（EFS）in stage IIIA non-small cell lung cancer (NSCLC). Further to compare the amount of serum DNA in patients with stage IIIa NSCLC before, during and after chemotherapy, before and after radiotherapy (in arm A) and during follow-up in patients randomized into the trial and to correlate the Deoxyribonucleic acid (DNA) variation with tumor response, remission duration and overall survival.
Interventions
RADIATIONneoadjuvant chemoradiotherapy
Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Histologically proven NSCLC with nodal metastases: T1-3N2M0 * Performance status 0-1 * Patient medically fit enough for protocol therapy, including operability * Age 18-75 * Written informed consent * No previous chemo- or radiotherapy
Exclusion criteria
* Patients with prior or concomitant malignancies Allowed are: non-melanomatous skin cancer, adequately treated in situ cervical cancer or any other neoplastic diseases with disease-free interval ³ 5 years. * Presence or history of any distant metastasis * Unstable cardiac disease requiring treatment, congestive heart failure or angina pectoris even if medically controlled, significant arrhythmia, or prior history of myocardial infarction in the last 3 months * History of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent * Active uncontrolled infection * Uncontrolled diabetes mellitus * Gastric ulcers * Preexisting peripheral neuropathy (\> grade 1) * Other serious underlying medical condition which could impair the ability of the patient to participate in the trial * Concurrent treatment with other experimental drugs * Pretreatment with any other cytostatic therapy * Previous radiotherapy to the chest * Concurrent treatment with prednisone (or equivalent) except: for the prophylactic medication regimen before treatment, treatment of acute hypersensitivity reactions or chronic treatment (initiated \> 6 months prior to trial entry) at low dose (£ 20 mg methylprednisolone or equivalent) * Definite contraindications for the use of corticosteroids as premedication * Treatment within a clinical trial within 30 days prior to trial entry * Socioeconomic or geographic circumstances that may prohibit proper staging, treatment or follow-up procedures * Pregnancy, lactation period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival | five years |
Secondary
| Measure | Time frame |
|---|---|
| Operability | within the first 30 days (plus or minus 3 days) after surgery |
| Postoperative 30-day mortality | 30 days after treatment |
| Toxicity | 30 days after treatment |
Contacts
Primary ContactLuo qingquan, M.D
Outcome results
None listed